Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib DDI Study with COC, Metformin, Digoxin, and Esomeprazole
NCT06793943Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zasocitinib in psoriasis (4 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration up to 120 hours, Area Under the Plasma Concentration-time Curve from Time 0 to Infinity up to 120 hours and 1 more. Started Jan 2025; status: completed.
02
Drugs
zasocitinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06793943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793943.